Compare Novartis AG (NVS) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Novartis AGTrade

Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Oxford Lane Capital Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Oxford Lane Capital Corp trades at $8.82 (market cap $866.15M). The key difference: Novartis AG is far larger — about 335.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (27.06%). Which is the better fit depends on your goals.

	NVS	OXLC
Market Cap	$290.25B	$866.15M
Sector	Health	Financials
52-Week High	$168.62	$19.90
52-Week Low	$113.50	$8.15
Enterprise Value	$330.27B	—
Dividend Yield	3.17%	27.06%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

OXLC

Oxford Lane Capital to release Q1 fiscal earnings and hold conference call on July 28, 2026GlobeNewsWire · 13 hours agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.